Compare Fox Corp Class A (FOXA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs BIO-TECHNE Corp — how do they compare? Fox Corp Class A trades at $56.64 (market cap $22.28B), while BIO-TECHNE Corp trades at $71.77 (market cap $11.14B). The key difference: Fox Corp Class A is far larger — about 2× BIO-TECHNE Corp's market cap, and Fox Corp Class A pays the higher dividend (1%). Which is the better fit depends on your goals.
| FOXA | TECH | |
|---|---|---|
Market Cap | $22.28B | $11.14B |
Sector | Media | Health |
52-Week High | $76.11 | $71.48 |
52-Week Low | $48.79 | $43.31 |
Enterprise Value | $26.25B | $11.22B |
Dividend Yield | 1% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOXA) trades at $56.69, up 3.32% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q1 2026 results, beating EPS estimates, and completed a transformative $22 billion acquisition of Roku in June 2026. Fundamentals show revenue growth to $16.3B in 2025 with a 13.88% net margin, while valuation metrics appear reasonable with a P/E of 14.73 and EV/EBITDA of 8.42.
The outlook balances strategic positioning through the Roku acquisition against integration risks and leverage concerns. Analyst consensus is evenly split between Buy and Hold with a $67.80 price target suggesting 19.6% upside, but technical indicators remain bearish and projected 2026 cash flow turns negative. Key risks include streaming competition, advertising cyclicality, and debt servicing from the Roku deal.
Bio-Techne (TECH) trades at $71.69, up 0.65% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, though RSI indicates potential overbought conditions. Fundamentally, revenue held at $1.22B in 2025, but net income fell to $73.40M with margin compression. Analysts are split 50/50 buy/hold with a $67.75 consensus target, below the current price, reflecting acquisition uncertainty.
The outlook hinges on the Merck deal closure at $73.00, offering a 1.8% premium from current levels. Risks include shareholder litigation challenging the transaction's fairness and regulatory approval delays. Without the deal, high P/E of 102.12 and declining profitability pose downside risks. The acquisition provides a near-term floor, but execution volatility remains a concern for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
